Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Krischan Hudson"'
Autor:
Elizabeth R. Volkmann, Christopher P. Denton, Martin Kolb, Marlies S. Wijsenbeek-Lourens, Claire Emson, Krischan Hudson, Anthony J. Amatucci, Oliver Distler, Yannick Allanore, Dinesh Khanna
Publikováno v:
European Respiratory Review, Vol 33, Iss 172 (2024)
Lysophosphatidic acid (LPA)-mediated activation of LPA receptor 1 (LPAR1) contributes to the pathophysiology of fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc). These diseases are associated with high morbid
Externí odkaz:
https://doaj.org/article/7dad0459aeb649318b278eb58358677c
Autor:
Andrea Mantsios, Miranda Murray, Tahilin S. Karver, Wendy Davis, Noya Galai, Princy Kumar, Susan Swindells, U. Fritz Bredeek, Rafael Rubio García, Antonio Antela, Santiago Cenoz Gomis, Miguel Pascual Bernáldez, Maggie Czarnogorski, Krischan Hudson, Nicki Walters, Deanna Kerrigan
Publikováno v:
BMC Health Services Research, Vol 21, Iss 1, Pp 1-14 (2021)
Abstract Background Long-acting injectable antiretroviral therapy (LA ART) has been shown to be non-inferior to daily oral ART, with high patient satisfaction and preference to oral standard of care in research to date, and has recently been approved
Externí odkaz:
https://doaj.org/article/9e71a923e6fb41a7abd953d3f6b71e1e
Autor:
Martha Hernandez-Illas, Daniel Baltrukonis, Krischan Hudson, Michelle Rossulek, Roberto A. Calle, Veena Somayaji, Jennifer Q. Dong, Yali Liang
Publikováno v:
British Journal of Clinical Pharmacology. 80:1051-1063
Aims The aim of the present study was to evaluate the pharmacokinetics/pharmacodynamics (PK/PD), safety and tolerability of single intravenous (IV) doses of PF-05231023, a long acting fibroblast growth factor 21 (FGF21) analogue being developed for t